Novo will turn to the projects
Novo Nordisk is very vague about which disease areas the group’s deal with Genmab will target, but VP of Global Research, Peter Kurtzhals, is delighted with the new partnership.
BY STEFAN SINGH KAILAY
Senior Vice President of Global Research, Peter Kurtzhals, is delighted with the deal Novo Nordisk struck with its countrymen from Genmab last week concerning the biotech’s Duobody technology platform, as it is just the type of the technology the diabetes group has been looking for. Aside from that, the VP is very secretive about the new collaboration.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Genmab and Novo team up in massive new deal
For abonnenter
